Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
01
08
2018
revised:
28
09
2018
accepted:
08
11
2018
pubmed:
15
11
2018
medline:
21
4
2020
entrez:
15
11
2018
Statut:
ppublish
Résumé
We assessed serum concentrations of the receptor activator of NFκB ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG), two proteins implicated in the development and progression of breast cancer, in 509 patients with primary, nonmetastatic breast cancer. Then the results were evaluated with regards to the occurrence of bone metastases, the presence of disseminated tumor cells (DTC) in the bone marrow, survival, and risk of developing metastatic disease. Before surgery, two bone marrow aspirates were analyzed for DTC using density centrifugation followed by immunocytochemistry (pan-cytokeratin antibody A45-B/B3). RANKL and OPG levels in the serum were measured by ELISA. RANKL levels were significantly lower in women >60 years ( These findings warrant further investigation as they provide a rationale for novel diagnostic or therapeutic approaches.
Identifiants
pubmed: 30425091
pii: 1078-0432.CCR-18-2482
doi: 10.1158/1078-0432.CCR-18-2482
doi:
Substances chimiques
Biomarkers, Tumor
0
Osteoprotegerin
0
RANK Ligand
0
TNFRSF11B protein, human
0
TNFSF11 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1369-1378Informations de copyright
©2018 American Association for Cancer Research.